India Supreme Court: Government Commits to 30% Cancer Drug Margin Cap

• The Indian government committed to the Supreme Court to implement a 30% trade margin cap on specific cancer drugs, with the measure formally notified on October 17, 2026, and revised prices effective from November 9, 2026.
• This measure addresses concerns over hospitals selling anti-cancer drugs at markups ranging from 170% to over 700%.
• The Ministry of Chemicals and Fertilizers highlighted significant information and bargaining asymmetries between patients and healthcare providers.
• The Supreme Court has urged for a broader examination of drug pricing, extending beyond just anti-cancer medications to the entire pharmaceutical sector.
• Existing drug prices in India are regulated under the Drugs (Prices Control) Order, 2013, which falls under the Essential Commodities Act, 1955.

The Supreme Court has urged for a broader examination of drug pricing, extending beyond just anti-cancer medications to the entire pharmaceutical sector.

The Indian government has committed to implementing a 30% trade margin cap on a specified list of cancer drugs, a measure that was formally notified on October 17, 2026, with revised prices set to take effect from November 9, 2026. This decision was conveyed to the Supreme Court of India in response to ongoing concerns regarding exorbitant pricing practices within the healthcare sector. The government's submission highlighted that hospitals frequently procure medicines from manufacturers offering the highest trade margins, subsequently reselling these essential anti-cancer drugs to patients at significantly inflated maximum retail prices (MRPs), with markups often ranging from 170% to over 700%.

This regulatory intervention aims to curb excessive markups on crucial anti-cancer medication while simultaneously ensuring that reasonable margins are maintained across the supply chain. The Solicitor General informed the Supreme Court that the list of drugs subject to this 30% trade margin cap would not be static; instead, it would undergo periodic updates to incorporate additional medicines based on evolving market conditions and public health requirements. However, inexpensive drugs are intended to be excluded from this specific capping mechanism.

The core issue stems from the inherent disadvantage faced by patients, who possess limited bargaining power and insufficient knowledge regarding drug alternatives and their true costs when dealing with hospitals. This information asymmetry allows for the prevalence of such high markups, particularly in the context of life-saving treatments. The proposed India Supreme Court cancer drug margin cap is a direct response to these documented malpractices.

Drug prices in India are currently governed by the Drugs (Prices Control) Order, 2013, which operates under the broader framework of the Essential Commodities Act, 1955. In an affidavit filed by the Ministry of Chemicals and Fertilizers concerning a pending case on capping all medicine and medical consumable prices, the government acknowledged the competitive nature of the Indian drug market. It noted that substantial competition typically negates the need for price regulation, often leading to some of the lowest drug prices globally.

However, the affidavit also underscored a critical distinction: the unique characteristics of health treatment and pharmaceutical products. These sectors are marked by significant information and bargaining asymmetries between patients on one side, and retail pharmacies, hospital pharmacies, hospitals providing treatment, and doctors on the other. This imbalance creates an environment where price exploitation can occur despite overall market competitiveness.

Beyond medicines, the affidavit also brought to light similar concerns regarding medical consumables within hospitals. These items frequently exhibit even higher margins, often ranging from 100% to over 1000%. Hospitals reportedly tend to purchase consumables that carry a high MRP and margin, even if their actual cost to the distributor or hospital is low. While hospital supplies are typically bundled into package costs for major procedures under government schemes or insurance, where rates are negotiated, patients making direct payments are often billed separately at the full MRP, exacerbating the financial burden.

During the hearing of a petition addressing the sale of essential medicines at inflated prices, a bench comprising Justices Vikram Nath and Sandeep Mehta expressed a clear mandate for a more comprehensive approach to drug pricing. The Supreme Court questioned why price-control measures were being confined solely to anti-cancer drugs and inquired about the absence of similar considerations for other categories of medicines.

The Court further challenged the rationale behind allowing pharmaceutical manufacturers to unilaterally set drug prices, questioning how such a system ultimately benefits patients. It specifically sought justification for the prevalence of higher medicine prices across the market. The bench emphatically stressed that the regulatory exercise should not conclude with anti-cancer medicines but must extend to encompass the entire pharmaceutical market, calling for a broader scrutiny of drug pricing mechanisms. This judicial stance signals a potential expansion of anti-cancer drug price regulation India to a wider array of pharmaceutical products and medical consumables. The matter is scheduled to be heard again on October 27, 2026.

Lawyers advising pharmaceutical companies and hospitals in India should monitor the upcoming notification of the 30% trade margin cap on cancer drugs and prepare for potential expansion of price controls to other medicines and medical consumables, as indicated by the Supreme Court's broader scrutiny. Compliance officers must review current pricing strategies and supply chain agreements to ensure adherence to new regulations and mitigate exposure to malpractice claims.

Source: Reporting based on Supreme Court submissions.